Function Health: Specific Patient Profiles That Should Avoid This Service

What Is Function Health and How Does the Model Work?

Function Health operates as a membership platform that ships a requisition order to members, who then visit a partner draw site to collect blood, urine, or saliva samples. Results are returned through a proprietary app with brief interpretive copy. The company was co-founded by cardiologist Mark Hyman, MD, and Peter Attia-adjacent longevity medicine advocates, and it markets itself as a way to "own your health data."

The Business Model in Plain Terms

Members pay a flat annual fee. For that fee they receive one large panel draw per year plus an optional second draw. No synchronous physician consultation is required before ordering. Results include brief interpretive text generated through a combination of clinician review and algorithmic flagging. The platform does not prescribe medications directly but may recommend specialist follow-up for abnormal values.

Regulatory and Credentialing Status

Labs used by Function Health operate under CLIA (Clinical Laboratory Improvement Amendments) certification, as required by federal law for any facility that performs testing on human specimens [1]. CLIA certification governs laboratory quality but does not regulate how a platform orders tests, interprets them, or communicates them to consumers. The FDA does not require approval for lab-ordering platforms, only for the test kits or analyzers themselves [2]. As of January 2025, Function Health is not accredited by the Better Business Bureau and does not carry LegitScript Healthcare certification, a voluntary standard used to signal compliance with pharmacy and telehealth regulations.

This matters clinically. LegitScript certification requires platforms to demonstrate that prescribing (where applicable) follows evidence-based standards and that physician oversight is documented [3]. Its absence is not proof of wrongdoing, but it removes one independent accountability layer.

Is Function Health Legitimate?

Function Health is a real, operating company that uses CLIA-certified laboratories and returns genuine biomarker data. "Legitimate" in a consumer sense, meaning the labs are real and the results are not fabricated, appears to be true based on available reporting and the CLIA framework [1]. The more precise clinical question is whether the oversight model is adequate for the patient population using it.

What the Evidence Says About DTC Lab Testing Broadly

The peer-reviewed literature on DTC testing is cautious. A 2019 systematic review in the Journal of General Internal Medicine found that DTC genetic and lab tests produced downstream healthcare utilization increases without clear improvements in clinical outcomes [4]. A separate analysis published in JAMA Internal Medicine noted that incidental findings from broad panels prompted unnecessary follow-up imaging and procedures in a meaningful proportion of recipients [5].

The U.S. Preventive Services Task Force (USPSTF) explicitly states that broad screening panels ordered outside of clinical indication are not supported by evidence for average-risk adults in several biomarker categories, including thyroid function screening in asymptomatic adults and routine homocysteine measurement [6]. Function Health panels include both.

What Independent Complaints Reveal

Consumer complaints about Function Health, visible on Trustpilot and Reddit forums as of late 2024, cluster around three themes: results flagged as abnormal with no clear next step offered, difficulty reaching a human clinician for interpretation, and concerns about whether the company's algorithmic interpretive copy constitutes medical advice. None of these complaints have resulted in publicized regulatory action as of this writing, but they point to the structural weakness of asynchronous-only oversight.

Patient Profiles That Should Avoid Function Health

This is the section most relevant to clinical decision-making. The following profiles are defined based on published guidelines and the specific gaps in the Function Health model.

Profile 1: Patients on Anticoagulants or Who Have Bleeding Disorders

Any phlebotomy carries bleeding risk. For patients on warfarin, apixaban, rivaroxaban, or direct thrombin inhibitors, venipuncture at a third-party draw site staffed by personnel who may not have access to the patient's INR or recent coagulation history introduces risk. The American Society of Hematology notes that patients with underlying coagulopathies or supratherapeutic anticoagulation require pre-procedure INR or anti-Xa review before elective phlebotomy [7]. Function Health's intake process does not systematically capture current anticoagulation status or recent INR values before sending a patient to a draw site.

Profile 2: Pregnant Individuals

Reference ranges for nearly every biomarker Function Health measures change substantially during pregnancy. Hemoglobin, ferritin, TSH, albumin, alkaline phosphatase, and glucose all shift in ways that make standard adult reference ranges misleading [8]. A pregnant person receiving a flagged low hemoglobin result interpreted against a non-pregnant reference range may receive unnecessary alarm, or conversely, a normal-for-pregnancy value may be missed as pathological by algorithmic flagging calibrated to the general adult population. Obstetric societies including ACOG recommend that lab testing during pregnancy be ordered and interpreted by a clinician familiar with gestational reference intervals [9].

Profile 3: Individuals With Active or Recovering Eating Disorders

Eating disorder clinicians and the Academy for Eating Disorders have published consensus guidance warning against self-directed weight, body composition, or metabolic monitoring in patients with active anorexia nervosa, bulimia nervosa, or atypical anorexia [10]. Function Health's panel includes body composition correlates, metabolic rate proxies, lipid subfractions, and inflammatory markers. Receiving a low BMI-associated inflammatory value or a low leptin level could reinforce disordered cognition. Patients fewer than 12 months into eating disorder recovery face the same risk. The platform has no screening mechanism to identify this population at sign-up.

Profile 4: Patients Already Under Active Specialist Care for the Condition Being Tested

A patient with known hypothyroidism managed by an endocrinologist does not benefit from receiving a TSH result through a separate platform with no access to their medication history. The risk is dual: the patient may adjust their levothyroxine dose based on the Function Health result without telling their prescribing physician, or they may present a discordant result to their specialist that generates confusion rather than insight. The same logic applies to patients with known dyslipidemia receiving statin therapy, patients with CKD having eGFR monitored by a nephrologist, and patients with known autoimmune conditions whose ANA titers are already tracked. Adding a parallel data stream with asynchronous-only oversight does not add value and may disrupt coordinated care.

Profile 5: Patients With High Health Anxiety or Illness Anxiety Disorder

Illness anxiety disorder (formerly hypochondriasis) affects approximately 1.3 to 10 percent of the general population depending on diagnostic criteria used [11]. Broad biomarker panels reliably generate at least one out-of-range value in otherwise healthy individuals simply due to statistical probability. With 100 biomarkers tested at standard 95 percent reference intervals, a healthy person has roughly a 99.4 percent chance of receiving at least one flagged value by chance alone (calculated as 1 minus 0.95 to the power of 100). For a patient with baseline health anxiety, that flag may trigger a cycle of medical visits, repeat testing, and psychological distress that outweighs any genuine health benefit.

Profile 6: Uninsured or Underinsured Patients Who May Act on Results Without Follow-Up Access

When Function Health returns an abnormal ferritin, a flagged PSA, or an elevated fasting insulin, appropriate follow-up may require a physician visit, repeat testing, imaging, or specialist referral. Each of those steps costs money. For a patient without insurance who paid $499 for the Function Health membership expecting it to replace traditional care, the flagged result creates an obligation they may not be able to meet. The platform's own marketing language implies the service is a complement to, not a replacement for, traditional medical care. But the $499 price point and the framing around "owning your health data" may attract patients who view it as a substitute.

Profile 7: Pediatric Patients or Individuals Under Age 18

Function Health's terms of service restrict membership to adults 18 and older. This is clinically appropriate given that pediatric reference ranges differ substantially from adult ranges for nearly every biomarker in the panel [12]. Parents seeking broad metabolic testing for minors should work with a pediatrician or pediatric endocrinologist who uses age-specific and sex-specific reference intervals.

Specific Biomarkers Where the Asynchronous Model Fails

Not all 100-plus biomarkers carry equal risk when communicated asynchronously. Several categories warrant specific caution.

Troponin and Cardiac Biomarkers

High-sensitivity troponin I and troponin T are included in some longevity panels. These markers require acute clinical context. An elevated troponin in a patient with chest pain is a medical emergency requiring same-day evaluation. An isolated mildly elevated troponin in a sedentary but asymptomatic person has a different differential that includes demand ischemia, myocarditis, pulmonary embolism, and chronic kidney disease [13]. Receiving an elevated troponin result through an app, with interpretive copy suggesting "consult your physician," does not replicate the clinical triage that an emergency or inpatient physician applies. The American College of Cardiology notes that high-sensitivity troponin assays require serial measurement and clinical correlation before any diagnosis is made [14].

Cancer Marker Panels

Function Health includes PSA, CA-125, CA 19-9, AFP, and CEA. None of these markers is approved by the FDA as a standalone population-screening tool. The FDA's own guidance on tumor markers notes that elevated levels require tissue diagnosis and should not be used to diagnose cancer independently [15]. USPSTF specifically recommends against routine PSA screening in men aged 70 and older and recommends shared decision-making only for men aged 55 to 69, based on evidence that screening in the broader population produces more harm than benefit from unnecessary biopsies and treatment [16]. Delivering PSA results to men outside this narrow shared-decision-making context, without a physician present to contextualize them, runs counter to current guideline recommendations.

Hormone Panels Without Clinical Context

Total testosterone, free testosterone, DHEA-S, estradiol, progesterone, and LH are all included in Function Health's standard panel. These values are highly sensitive to time of draw, stress, recent illness, and age. A total testosterone of 280 ng/dL in a 38-year-old male is clinically different depending on whether that value is accompanied by symptoms of hypogonadism, was drawn at 8 AM in a fasted state, and represents a stable baseline rather than a transient dip. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that diagnosis requires two morning fasting testosterone measurements plus symptom evaluation, not a single result [17]. Function Health draws at a time determined by patient convenience, not by guideline-specified protocols.

What Function Health Does Well (and Why That Doesn't Eliminate the Risks)

The platform solves a real access problem. Many primary care physicians cannot justify ordering 100-biomarker panels for asymptomatic adults under insurance billing codes, and patients curious about their APOB, Lp(a), or omega-3 index have historically had to pay out-of-pocket through fragmented sources or find a concierge physician. Function Health aggregates that access at a lower price than most concierge medicine practices.

The company also returns genuinely useful data for a specific profile: a healthy adult with no active diagnoses, an established primary care relationship, no bleeding disorders, no history of disordered eating, and sufficient health literacy to bring results to a physician for interpretation. For that person, the $499 price point and the breadth of the panel may be a reasonable investment.

The problem is that the platform's marketing does not restrict itself to that narrow profile. Its advertising reaches broad consumer audiences, and the sign-up process does not exclude the high-risk profiles described above.

Questions to Ask Before Signing Up

Before committing to a Function Health membership, any prospective member should be able to answer yes to each of these questions.

Do you have an established primary care physician or internist who has agreed to review your results with you? Do you have no active diagnoses that are already being monitored by a specialist? Are you not currently pregnant, not on anticoagulants, and not in active treatment or recent recovery for an eating disorder? Do you understand that at least one biomarker value in a 100-biomarker panel will be flagged outside the reference range by chance, even if you are entirely healthy? Are you prepared to pay out-of-pocket for any follow-up testing or specialist visits that the results prompt?

If any answer is no, a direct conversation with a primary care physician about which specific biomarkers warrant testing based on your individual risk factors is the medically appropriate first step.

Regulatory and Oversight Gaps Worth Watching

The FTC has taken action against several DTC health companies for deceptive marketing claims related to diagnostic testing. In 2019, the FTC and FDA jointly warned companies marketing DTC genetic tests for medication sensitivity (pharmacogenomics) that overstating clinical utility violated FTC Act Section 5 [18]. Function Health has not been the subject of a publicized FTC or FDA enforcement action as of January 2025, but the regulatory framework under which DTC lab platforms operate continues to evolve.

State-level regulations add additional complexity. Some states, including New York, New Jersey, and Maryland, require a licensed physician to order laboratory tests, meaning residents of those states may face different service delivery than members in other states [19]. Function Health addresses this through contracted physician networks, but the quality and availability of that physician oversight varies by state.